1997
Treatment of Uveitis by Oral Administration of Retinal Antigens: Results of a Phase I/II Randomized Masked Trial
Nussenblatt R, Gery I, Weiner H, Ferris F, Shiloach J, Remaley N, Perry C, Caspi R, Hafler D, Foster C, Whitcup S. Treatment of Uveitis by Oral Administration of Retinal Antigens: Results of a Phase I/II Randomized Masked Trial. American Journal Of Ophthalmology 1997, 123: 583-592. PMID: 9152063, DOI: 10.1016/s0002-9394(14)71070-0.Peer-Reviewed Original ResearchConceptsPhase I/IISoluble retinal antigenTreatment of uveitisRetinal antigensRetinal S-antigenS-antigenStudy endpointImmunosuppressive therapyOral administrationPhase I/II studyMasked trialOcular inflammatory attacksStandard immunosuppressive therapySystemic immunosuppressive therapyPrimary study endpointSecondary study endpointsMain study endpointImmunosuppressive medicationsII studyInflammatory attacksOcular inflammationCytotoxic medicationsImmunosuppressive agentsEndogenous uveitisTreatment groups
1993
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, Fisher M, Birnbaum G, McArthur J, Butler R, Moore M, Sigsbee B, Safran A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43: 910-8. PMID: 8388090, DOI: 10.1212/wnl.43.5.910.Peer-Reviewed Original ResearchConceptsMajority of patientsInduction regimenTreatment failureTreatment groupsCyclophosphamide pulse therapyPatients 40 yearsPatients ages 41Progressive MS patientsPulse cyclophosphamide therapyPatients age 18Progressive multiple sclerosisNonbooster groupPulse therapyCyclophosphamide therapyProgressive MSMS patientsMultiple sclerosisDisease progressionSignificant benefitsAge 41Subsequent progressionPatientsInitial stabilizationAge 18Regimen